Annual Drug Patent Expirations for IMBRUVICA Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. It is available from one supplier. There are forty-one patents…
Source
Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen…
Source
Annual Drug Patent Expirations for DEFINITY+RT Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are nine…
Source
Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are nine patents…
Source
This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…
Source
Which pharmaceutical companies have the most drug patents in Serbia? Read Post »
A recent article in Communications of the ACM explores opportunities for “Permissionless innovation” in pharmaceuticals. “Permissionless innovation” refers to the freedom to explore new technologies or businesses without needing prior…
Source
Unleashing Innovation: The Case for Permissionless R&D in Pharma Read Post »
Annual Drug Patent Expirations for BIKTARVY Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are twelve…
Source
Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are ten…
Source
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPatentWatch.com
Source
Annual Drug Patent Expirations for JORNAY+PM Jornay Pm is a drug marketed by Ironshore Pharms and is included in one NDA. It is available from one supplier. There are fifteen…
Source
Get new actionable insights and updates from BiotechBlog
